Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: PR 350; RP 343

Latest Information Update: 21 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyoto University; POLA PHARMA
  • Developer POLA PHARMA; Shuttle Pharmaceuticals
  • Class Imidazoles; Radiosensitisers
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Research Pancreatic cancer

Most Recent Events

  • 21 Aug 2017 Doranidazole is still in phase IIa trial for Non-small cell lung cancer in Japan
  • 15 Aug 2017 Doranidazole licensed to Shuttle Pharma in USA
  • 15 Aug 2017 Dranidazole licensed to Shenzhen Main Luck Pharmaceuticals in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top